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KECENDERUNGAN GENETIK M2 ANNEXIN A5 HAPLOTIP DALAM 
KEGUGURAN IDIOPATIK BERULANG DI KALANGAN MELAYU DI 
MALAYSIA  
 
ABSTRAK 
 
Keguguran berulang merupakan suatu keadaan lazim yang berlaku di mana 
faktor-faktor trombofilia keturunan konvensional yang telah dikenal pasti bukannya 
punca utama keguguran di populasi Malaysia. Haplotip M2/ANXA5, suatu variasi pada 
kawasan promoter gen Annexin A5 (ANXA5), telah diimplikasikan sebagai suatu 
faktor kecenderungan bagi keguguran idiopatik berulang. ANXA5 ialah protein 
antikoagulan plasenta yang terikat pada permukaaan “syncitiotrophoblasts” untuk 
mengelakkan episod trombosis yang akan menyebabkan keguguran berulang. Di 
dalam kajian ini, kadar kehadiran haplotip M2/ANXA5 adalah 42.2% di kalangan 
populasi melayu, 34.9% untuk kategori kawalan parus. Apabila membandingkan kadar 
M2/ANXA5 di dalam kategori pembawa keguguran berulang primer dan sekunder 
dengan pembawa M2/ANXA5 di kalangan populasi rawak, nisbah ganjil pada 1.52 
(dengan sela keyakinan 95%: 1.1 sehingga 2.1) telah dinilaikan. Nisbah ganjil yang 
tertinggi ialah 1.97 (dengan sela keyakinan 95%: 1.3 sehingga 3.1) telah didapati 
apabila dibandingkan dengan kawalan parus. Pertambahan bilangan alel M2/ANXA5 
akan meningkatkan risiko keguguran berulang pada pasangan, terutamanya jika 
kedua-dua pasangan merupakan pembawa M2/ANXA5. Kajian ini telah mengesahkan 
peranan haplotip M2/ANXA5 sebagai faktor kecenderungan untuk mengalami 
keguguran berulang di kategori primer dan sekunder pada awal kehamilan di kalangan 
populasi Melayu. Berikutan dengan itu, kuantifikasi plasma ANXA5 di kalangan 
subjek yang mengandung dan tidak mengandung telah dijalankan untuk menentukan 
potensi nilai diagnostiknya. Namun begitu, keputusan yang didapati menunjukkan 
xv 
 
bahawa tiada perbezaan yang ketara dalam paras ANXA5 di plasma di antara wanita 
yang tidak mengandung, subjek kawalan parus mengandung dan wanita yang 
mengalami keguguran berulang, walaupun terdapat trend yang menunjukkan 
perbezaan yang ketara dalam paras ANXA5 di plasma di antara pembawa M2/ANXA5 
dan bukan pembawa (p = 0.02, dengan pembetulan post-hoc Bonferoni) di dalam 
analisis ‘dalam-kumpulan’. Oleh itu, paras ANXA5 di plasma tidak mempunyai nilai 
diagnostik bagi menilai risiko keguguran berulang jika dibandingkan dengan 
pendekatan genetik. Seterusnya, ujian tindakbalas rantai polimerase yang bergantung 
kepada RNase H2 telah dihasilkan sebagai ujian saringan haplotip M2/ANXA5. 
Akhirnya, untuk mengenalpasti hubungan di antara haplotip M2/ANXA5 dan 
keguguran berulang, satu analisis meta yang melibatkan 13 laporan kajian telah 
dilaksanakan. Sesungguhnya, keputusan menunjukkan bahawa haplotip M2/ANXA5 
merupakan faktor kecenderungan untuk megalami keguguran berulang (OR: 1.597, 95 
% CI: 1.083 hingga 2.354, p = 0.018). Secara keseluruhannya, kajian ini telah 
mengesahkan bahawa haplotip M2/ANXA5 mempunyai kaitan dengan keguguran 
berulang pada awal kehamilan yang tidak dapat dijelaskan di kalangan populasi 
Melayu, khasnya apabila kedua-dua pasangan merupakan pembawa M2/ANXA5. Oleh 
itu, ia membuktikan bahawa ujian saringan haplotip M2/ANXA5 merupakan suatu 
ujian prognostik bagi penilaian risiko keguguran berulang, di mana ujian tindak balas 
rantai polimerase yang bergantung kepada RNase H2 telah dihasilkan bagi saringan 
tersebut.  
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GENETIC PREDISPOSITION OF M2 ANNEXIN A5 HAPLOTYPE IN 
RECURRENT PREGNANCY LOSS AMONG THE MALAYS IN MALAYSIA 
 
ABSTRACT 
Repeated Pregnancy Loss (RPL) is a prevalent condition where conventional 
hereditary thrombophilia factors have been ruled out in Malaysia population. 
M2/ANXA5 haplotype, a variation at the core promoter region of Annexin A5 
(ANXA5) gene, was suggested to be a predisposition factor for RPL. ANXA5 is a 
placenta anticoagulant protein which binds on the surface of syncitiotrophoblasts to 
prevent thrombotic events that would lead to RPL. In this study, the prevalence of 
M2/ANXA5 haplotype was 42.2% in Malay population and 34.9% for parous controls. 
When compared M2/ANXA5 clinically defined primary and secondary RPL carriers to 
M2/ANXA5 carriers in random populations, odds ratio of 1.52 (95% CI:1.1 to 2.1) was 
determined. The highest odds ratio of 1.97 (95% CI: 1.3 to 3.1) was obtained when 
compared to parous control. Increasing copy numbers of M2/ANXA5 alleles contribute 
a higher risk in RPL couples, especially when both partners were M2/ANXA5 carriers. 
This first study confirmed the proposed role of M2/ANXA5 haplotype as a 
predisposition factor for early primary and secondary RPL among Malay population. 
Following that, the quantification of the ANXA5 plasma in pregnant and non-pregnant 
subjects was carried out to seek its potential diagnostic value. However, the results 
showed no significant differences in ANXA5 plasma levels across non-pregnant, 
pregnant parous and RPL women, even though there was a trend of significant 
difference in the ANXA5 plasma levels between M2/ANXA5-carriers and non-carriers 
(p = 0.02, with post-hoc Bonferoni correction) in the ‘within-group’ analysis. Hence, 
ANXA5 plasma levels in maternal does not have a diagnostic value for RPL risk 
estimation as compared to the molecular approach. Next, a RNase H2-dependent PCR 
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was developed for the screening of M2/ANXA5 haplotype. Finally, to ascertain the link 
between M2/ANXA5 haplotype and RPL, a meta-analysis involving 13 reported studies 
was carried out. Indeed, the results indicated that M2/ANXA5 haplotype is a 
predisposition factor for RPL (OR: 1.597, 95% CI: 1.083 to 2.354, p = 0.018). 
Collectively, this work confirmed women with M2/ANXA5 haplotype is associated 
with unexplained early RPL. Hence, it warrants the screening of M2/ANXA5 haplotype 
as a prognostic test for the risk assessment of RPL, where a single tube RNase H2 
dependent PCR was developed for this screening.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Pregnancy Loss 
Pregnancy loss/miscarriage described a loss of the conceptus from fertilized ovum to 
neonate that failed to progress, resulting in death and expulsion of the embryo or fetus 
that weigh 500 g or less within 20 gestational weeks. Miscarriage is a major problem 
in women’s health. About 25% of all clinically recognizable pregnancies ended in 
miscarriage (ASRM, 2008). This is a trauma for couples who are seeking parenthood 
and remain a formidable clinical challenge to their physician. The couples are affected 
with significant emotional, social and even the economic impact. It has been reported 
that 5% of women may encounter two or more losses repeatedly, and 1% of women 
even have three or more losses throughout their reproductive age (Stirrat, 1990). 
 
1.2 Repeated pregnancy loss 
Thus far, there is no consensus achieved on the definition of repeated pregnancy loss 
[(RPL), (Farquharson et al., 2005, Stirrat, 1990)]. American College of Obstetrics and 
Gynaecology (ACOG) defined RPL as two or more consecutive miscarriages (ACOG 
practice bulletin, 2002). In addition, RPL may also be grouped into three sub-
conditions: primary RPL; secondary RPL and tertiary RPL. Primary RPL refers to 
multiple pregnancy losses in which a patient has never had a live birth, while 
secondary RPL refers to multiple pregnancy losses with at least a live birth previously, 
and tertiary RPL refers to multiples pregnancy losses in a patient who has had 
interspersed with pregnancies that have progressed beyond 20 weeks’ gestation 
(Practice Committee of the ASRM, 2008, Carp, 2007). 
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RPL is a complex and multifactorial obstetric problem with polygenic 
background (Figure 1.1). It has been shown to be associated with genetics, age, 
antiphospholipid syndrome (APS), uterine anomalies, hormonal or metabolic 
disorders, infection and autoimmunity. However about 50% of RPL cases are still 
unexplained, or idiopathic including non-antiphospholipid syndrome of heritable 
thrombophilia origin (Ford and Schust, 2009).  
 
 
 
Figure 1.1 Etiology of RPL. 
 
 
1.3 Heritable thrombophilia and RPL 
Heritable thrombophilia has been reported to be one of the major cause for unexplained 
RPL (Kupferminc  et al., 1999, Preston et al., 1996). Predisposing factors of hereditary 
thrombophilia leading to venous thrombosis are discussed below.  
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1.3.1 Factor V Leiden mutation 
A missense mutation at the nucleotide position 1691 of Factor V gene (from G to A), 
resulted in a substitution of arginine (R) to glutamine (Q) at position 506 of the 
procoagulant protein. The site where activated protein C (APC) would normally cleave 
and inactivate procoagulant factor Va. This substitution partially causes resistant of 
the activated protein C (APC) anticoagulation properties, resulting in increased 
thrombin generation leading to a prothrombotic state. This prolong prothrombotic state 
would lead to venous or arterial thrombosis or RPL. 
Factor V Leiden (FVL) is one of the most common factor for heritable 
thrombophilia. However, its prevalence varied among the different ethnic groups. For 
example, it is common in Whites [3 to 15%, (Ridker et al., 1997b, Rees et al., 1995)] 
but rare in Africa and Asia descendant [≤ 1%, (Kujovich, 2010, Irani-Hakime et al., 
2000, Fujimura et al., 1995)]. Patients with FVL usually have an increased risk of 
venous thrombosis (from 3- to 100- fold) depending on their zygosity (Ridker et al., 
1997a, Griffin et al., 1993, Koster et al., 1993); the associations of FVL and RPL were 
reported to have odds ratio ranging from 0.5 to 9 (Said et al., 2010, Clark et al., 2008, 
Lindqvist et al., 2006, Dizon-Townson et al., 2006, Rai et al., 2001, Murphy et al., 
2000, , Wramsby et al., 2000, Foka et al., 2000, Kutteh et al., 1999, Brenner et al., 
1997, Balasch et al., 1997), indicating that carrier of FVL will have 0.5 to 9 times 
higher risk in experiencing RPL when compared to non-carrier. 
Indeed, a meta-analysis carried out by Rey et al. (2003) successfully showed 
that FVL was truly associated with early recurrent fetal loss (OR 2.01, 95% CI: 1.13 
to 3.58); and even higher in late non-recurrent fetal loss (OR 3·26, 95% CI: 1·82 to 
5·83). A year later, another meta-analysis (involving 16 reported studies) that was 
carried out by Kovalesky et al. (2004) also reported an OR of 2.0 (95% CI: 1.5 to 2.7) 
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in support for the association between FVL and RPL. Following that, Robertson et al. 
(2006) performed systematic review of 40 studies linking the associations of (a) FVL 
and RPL in first trimester loss (OR 1.91; 95% CI: 1.01 to 3.61); (b) FVL and non-RPL 
in second trimester loss (OR 4.12; 95% CI: 1.93 to 8.81). A recent systematic review 
and meta-analysis of prospective trials (10 studies) also reported an increased risk of 
late pregnancy loss among FVL carriers (OR 1.52, 95% CI: 0.80 to 1.25). All the above 
reports evidence the role of FVL as a contributing factor to recurrent pregnancy loss. 
 
1.3.2 Prothrombin G20210A mutation 
Prothrombin G20210A mutation is the second most common hereditary factor follows 
by FVL. Prothrombin is the precursor of thrombin in the coagulation system. A 
transition mutation from G to A at nucleotide 20210 of the 3’ untranlasted prothrombin 
gene; resulted in accumulation of messenger RNA (prolonged turnover) therefore 
increases concentration of prothrombin protein in plasma, which is, in turn, lead to the 
risk of thrombosis. 
The prevalence of the prothrombin mutation (PTm) in Europe is approximately 
1.7 to 3%. Heterozygous carriers of the 20210A allele have a 2- to 8- fold higher risk 
for venous thrombosis (Poort et al., 1996). Very few cases of homozygosity for this 
mutation have been described (Rosendaal et al., 1998). The first comprehensive meta-
analysis from Rey et al. (2003) showed that a significant association between PTm and 
RPL below 13 weeks of pregnancy (OR 2.70, 95% CI: 1.37 to 5.34) as well as with 
non-recurrent fetal loss after 20 weeks of gestation.  
Likewise, a meta-analysis from Kovalesky et al. (2004) reported OR 2.0 (95% 
CI: 1.0 to 4.0) in PTm and RPL in first 2 trimesters of pregnancy. Following that, 
Robertson et al. (2006) reported OR 2.49 (95% CI: 1.24 to 5.00) in early loss and OR 
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2.66 (95% CI: 1.28 to 5.53) in late loss. A recent systematic review and meta-analysis 
by Gao and Tao (2015) further confirmed a significant association with RPL, OR 1.81 
(95% CI: 1.26 to 2.6). They have reported an increase risk in European rather than 
Middle-Eastern, suggesting the screening of PTm should be group-specific (Gao and 
Tao, 2015).  
Individual carrying both FVL and prothrombin G20210A mutation has a 20 
folds increased risk for venous thrombosis. Hence, DNA analyses of both mutations 
are highly recommended for patients with personal or family history of thrombosis 
(McGlennen and Key, 2002, Press et al., 2002).  
 
1.3.3 Methylene tetrahydrofolate reductase C667T mutation 
Another hereditary thrombophilia factor is methylentetrahydrofolate reductase 
(MTHFR), which is involved in methionine metabolism. Homocysteine, a non-
protein-building sulfhydryl amino acid, is an intermediate product in this metabolism. 
Homocysteine could be demethylated or remethylated to methionine in the body to a 
balance methionine concentration. When body methionine is low, homocysteine will 
be remethylated to methionine by the addition of a methyl group from 
methyltetrahydrofolate via MTHFR (Rosenblatt, 1995).  
A mutation found at the nucleotide 677 from C to T in the methylene 
tetrahydrofolate reductase gene (a thermolabile MTHFR enzyme) changes its amino 
acid from alanine (A) to valine (V), which increase the levels of plasma homocysteine 
(hyperhomocysteinemia). This mutation causes approximately 50% reduction in 
enzyme activity at 37 °C while increased its thermolability at 46 °C, thus lead to a mild 
~ moderate hyperhomocysteinaemia (Frosst et al., 1995).  
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Hyperhomocysteinaemia is a risk factor for pre-eclampsia, placenta abruption 
and fetal neural-tube defects (van der Put et al., 1998). Initial studies suggested that 
homozygosity for MTHFR C677T could be related to pregnancy loss (Goodman et al., 
2006, Nurk et al., 2004); however, meta-analysis from Rey et al. (2003) and Roberston 
et al. (2005) reported that there is a lack of significant association with neither early 
nor late RPL. Due to insufficient evidence to association between pregnancy 
complications and MTHFR polymorphisms, therefore it was not included in the 
guidelines of the Italian society for Haemostasis and Thrombosis [(SISET) (Lussana 
et al., 2009)]. 
 
1.3.4 Activated protein C resistance (APCR) 
Activated protein C resistance (APCR) is another risk factor for clinical thrombosis 
(de Visser et al., 1999). Protein C is an anticoagulant protein that plays an important 
role in regulation of haemostasis balancing. It is activated when contacting with 
thrombin-thrombomodulin complex, termed activated protein C (APC). Later, APC 
binds to free protein S (cofactor) and formed a protein C/protein S complex, which 
degrades the activated form of factor V and factor VIII, resulted in low production of 
fibrin (Figure 1.2). Defects in protein C pathway molecules will lead to activated 
protein C resistant (APCR). The common causative factors are: (a) deficiencies of 
protein C and protein S (Chapter 1.3.5); (b) mutation in factors V gene - FVL 
(Chapter 1.3.1), factor V Cambridge (Williamson et al., 1998), Factor V Hong Kong 
and Factor V HR2 haplotype (de Visser et al., 2000, Bernardi et al., 1997); (c) elevated 
factor VIII levels in plasma (Laffan and Manning, 1996).   
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Figure 1.2 The anticoagulant pathway of protein C/protein S. Protein C was activated 
by thrombin-thrombomodulin (TM) complex. Then, activated protein C binds with its 
cofactor, free protein S, then degrades activated factors V and activated factor VIII. In 
addition, when thrombin binds thrombomodulin, thrombin loses its procoagulant 
functions (Adapted from Van Cott and Laposata, 1998).  
 
 
Lindqvist et al. (2006) showed that patients with APCR have an increase 
prevalence of second trimester fetal loss. APCR was the most common cause of 
inherited thrombosis accounting for 40% to 50% of cases thus suggesting APCR as a 
screening test in the assessment of RPL (Rosendorff and Dorfman, 2007, Rey et al., 
2003). 
 
1.3.5 Protein C, protein S and antithrombin deficiency 
Lastly, the deficiencies of protein C, protein S and antithrombin are heterogenous in 
nature and caused by several different genetic mutations. Their inherited traits are rarer 
than the genetic mutation described above yet they are contributing in clinical 
thrombosis (Rey et al., 2003). Protein C, protein S and antithrombin are the important 
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natural anticoagulants; Figure 1.3 shows that their involvement in maintaining the 
haemostasis system (Lipe and Ornstein, 2011).  
 
 
 
Figure 1.3 The relationship of natural anticoagulants and procoagulants between 
clotting and bleeding. In general, procoagulants (molecules that cause blood clots) are 
balanced by the natural anticoagulants (A). When there is a deficiency in one of the 
natural anticoagulants (B), the individual has an increased propensity to form abnormal 
blood clots (Adapted from Lipe and Ornstein, 2011). 
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Protein C and Protein S are vitamin-K-dependent anticoagulant proteins. 
Reduced levels/activities of protein C and protein S due to mutations would lead to the 
imbalance of haemostasis system and favour of a hypercoagulable state, hence 
increases the risk of thrombosis. In contrast, antithrombin is a non-vitamin K-
dependent protease that inhibits thrombin (primary target) and serine protease 
activated factors (factor II, IX, X, XI, and XII). The activity of antithrombin is 
markedly exerted by the presence of heparin resulted in anticoagulation (Nguyen et 
al., 2016, Palta et al., 2014). Deficiency of antithrombin level predispose to 
thromboembolic disease. 
Rey et al. (2003) in their meta-analysis confirmed the association of protein S 
deficiency with RPL (OR 14.72, 95% CI: 0.99 to 218.01) and late non-recurrent fetal 
loss (OR 7.39, 95% CI: 1.28 to 42.63). They have excluded protein C and antithrombin 
deficiencies as thrombophilia risk factors for pregnancy loss. Another meta-analysis 
failed to confirm the association of protein C, protein S and antithrombin deficiencies 
in late pregnancy loss. The prevalence of inherited protein C, protein S and 
antithrombin are extremely rare, therefore not many studies were carried out for RPL 
cases. 
In a nutshell, protein C, protein S and antithrombin III are natural 
anticogualants, the deficiencies of these factors are uncommon (Seligsohn  and 
Lubetsky 2001). Homozygosity of MTHFR (C677T) may lead to 
hyperhomocysteinemia but the association of RPL is relatively uncertain, even the 
SISET guidelines failed to recommend MTHFR as a screening test for pregnancy 
complications (Lussana et al., 2009). FVL and PTm are the two most common causes 
of inherited thrombophilia; they are very common among Caucasians, but rare in 
Asians and Africans (Kujovich, 2010, Rosendaal et al., 1998). Recently, a newly 
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discovered hereditary factor, termed M2/ANXA5 haplotype was proposed to be a new 
risk factor for RPL. 
 
1.4 Annexin A5 and its function 
Annexin A5 (ANXA5) gene is located at ~ 9 kb of human chromosome 4 q27. It consists 
of an untranslated exon with 12 coding exons (Cookson et al., 1994). The regulation 
of ANXA5 gene expression is yet not well known. The human ANXA5 gene expresses 
several transcripts and possesses a complex promoter that is subject to intricate 
regulation (Carcedo et al., 2001). Mutations of ANXA5 at -1C  T (rs11575945) 
variant was proposed to protect young individuals against myocardial infarction 
(González-Conejero et al., 2002).  
Annexin A5 (ANXA5) protein was first reported in bovine aortic endothelial 
cells further isolated and characterized in human placenta (Funakoshi et al., 1987). 
ANXA5 belongs to the member of “lipocortin” or “calpactin” family. The mRNA does 
not have a 5’-leader sequence, which is necessary for release into the extracellular 
environment. However, the protein can be found both extracellularly (blood 
circulation) and intracellularly (kidney, cardiac, placental and so on).  
Annexin A5 is a Ca2+ dependent anticoagulant protein and binds strongly to 
phosphatidylserine (PS) to prevent coagulation activation. PS is an anionic 
phospholipid that locates in the inner leaflets of cell plasma membrane; it will be 
exposed on cell membranes when trigger by (a) program cell death, (b) activated 
platelets and (c) on syncytiotrophoblasts (placenta-related-cells). Although the 
placenta is a foreign entity to the maternal immune system, this “natural” allograft is 
tolerated (Guleria and Sayegh, 2007). This is because Annexin A5 forms a highly 
ordered two-dimensional crystal structure over the phospholipids bilayer and blocks 
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the phospholipids from binding to other proteins [e.g. antiphospholipid (aPL) 
antibody] that could result it to be free of coagulation activation (Figure 1.4). 
Therefore, Annexin A5 acts as a protective shield in between the fetal and expected 
mother. 
 
 
 
Figure 1.4. Model of protective shield of ANXA5 using trophoblast cells and 
endothelial cells. (A) anionic phospholipids (minus signs) on the surface of the cell-
membrane creates a phenomenon to trigger coagulation pathway; (B) Annexin A5 
forms a highly ordered two-dimensional crystal structure over the anionic 
phospholipids and block the assembly of the phospholipid-dependent coagulation 
complexes, thereby inhibiting coagulation while absent of aPLs antibodies; (C) aPLs 
antibodies disrupt the ability of ANXA5 to cover on the phospholipid surface. This 
action reduces the binding affinity of ANXA5 and permits more anionic phospholipid 
to be available to form complexes with coagulation proteins. As a result, coagulation 
is accelerated and the development of thrombosis is promoted. TF denotes tissue factor 
(Adapted from Rand et al., 1997). 
 
 
1.4.1 ANXA5 gene promoter variants and their activities 
Although Rand et al. (1997) had proposed the model of protective shield model, why 
the aPLs antibody disrupts the ANXA5 protein shield was unclear. Hence, Bogdanova 
et al. (2007) initiated to perform a systematic screening of the coding and core 
promoter region of ANXA5 gene in 70 RPL patients.  
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Figure 1.5 describes structure of the ANXA5 gene core promoter region. The 
nucleotide 1 is at the first transcription start point of the gene, tsp 1 (Carcedo et al., 
2001), which corresponded to nucleotide 4956 of the gene (NG_032042.1); whereas 
the 5’- UTR began at -1 and proceeded in the negative direction (upstream from 
nucleotide 1). The determined SNPs were numbered according to the position of tsp 
1. 
 
 
 
Figure 1.5 Sequence of the ANXA5 gene core promoter region. Red circle is the tsp1. 
Bold capital letters are the nucleotides changed in M2/ANXA5 haplotype.  
 
 
They identified a constellation of 4 single-nucleotide polymorphisms (SNPs), 
-19 G A, rs112782763; 1 A  C, rs28717001; 27 T  C, rs28651243; and 76 G  
A, rs113588187 in the proximal core promoter region of the ANXA5 gene. From here, 
two forms of haplotypes were determined: (a) M1/ANXA5 haplotype: two SNPs (1 A 
 C, rs28717001 and 27 T  C, rs28651243); (b) M2/ANXA5 haplotype: four SNPs 
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(-19 G A, rs112782763; 1 A  C, rs28717001; 27 T  C, rs28651243; and 76 G 
 A, rs113588187). 
All substitutions were at the position of transcription factor consensus that may 
impair the ANXA5 promoter activity. To assess the promoter activities, M2/ANXA5 
haplotype and wild type ANXA5 promoter sequence were cloned and analyzed using 
luciferase Gene Reporter Assay kits. Bogdanova et al. (2007) showed a drastic 
reduction of the M2/ANXA5 haplotype activity (37 to 42% activity compared with wild 
type; Figure 1.6); whereas a less pronounced for M1/ANXA5 haplotype (57 to 62% 
activity compared with wild type).  
By comparing 70 RPL patients to controls subjects, they proposed the 
association of M2/ANXA5 haplotype with RPL, whereas M1/ANXA5 haplotype is not 
a predisposing factor. This was further confirmed by other studies later (Rogenhofer 
et al., 2012, Tüttelmann et al., 2013, Demetriou et al., 2015). 
 
 
 
Figure 1.6 Activity of ANXA5 gene promoter variants in luciferase reporter gene 
assay. N (wild-type) 100% activity. M1 (M1/ANXA5 haplotype) contains 57 - 62% 
activity; M2 (M2/ANXA5 haplotype) contains 37 - 42% activity (Adapted from 
Bogdanova et al., 2007). 
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Subsequently, Chinni et al. (2009) extracted placental RNA near to umbilical 
cord and reported that a 2-fold reduction of ANXA5 gene expression in the M2/ANXA5 
carrying placentas. Therefore, they concluded that M2/ANXA5 haplotype could 
influence ANXA5 gene expression not only in vitro but also ex-vivo (Chinni et al., 
2009). In the following year, Markoff et al. (2010) similarly reported a decrease 
amount of ANXA5 mRNA in M2/ANXA5 carrying placentas and further showed that 
no allelic compensation was observed when comparing the expression ratio of ANXA5 
N allele mRNA in heterozygous (N/M2) vs. ‘normal homozygous’ (N/N) placentas. In 
addition, M2/ANXA5 mRNA is reduced in all N/M2 samples regardless of the origin 
of the M2/ANXA5 allele (from paternal or maternal), indicating that the reduction was 
from embryonic rather than wholly maternal induced risk. Ota et al. (2013) confirmed 
the reduced expression of ANXA5 mRNA in M2/ANXA5 carrying placental; they 
further examined the expression of ANXA5 protein levels through immunostaining 
(Figure 1.7) and concluded that the protein levels were affected more by the placental 
genotype than the maternal genotype.  
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Figure 1.7 Immunostaining for ANXA5 protein in placental tissue sections. Chorionic 
villi were stained with a mouse anti-human ANXA5 monoclonal antibody. (A) Non- 
M2/ANXA5 carrying placenta from a non-M2/ANXA5 carrying mother; (B) Non-
M2/ANXA5 carrying placenta from an M2/ANXA5 carrying mother; (C) M2/ANXA5 
carrying placenta from a non-M2/ANXA5 carrying mother; (D) M2/ANXA5 carrying 
placenta from a M2/ANXA5 carrying mother. (Adapted from Ota et al., 2003). 
 
 
1.4.2 The prevalence of M2/ANXA5 haplotype 
Generally, the M2/ANXA5 carrier rates in European and Asian (Japanese) control 
populations ranged from 11% to 17% (Demetriou et al., 2015, Tüttelmann et al., 2013, 
Rogenhofer et al., 2012, Miyamura et al., 2011, Tiscia et al., 2009, Bogdanova et al., 
2007). When estimating the association between M2/ANXA5 haplotype and RPL, the 
odds ratios were from 1.5 to 2 when comparing to the general population of German 
(Tüttelmann et al., 2013, Bogdanova et al., 2007), UK (Demetriou et al., 2015), and 
Bulgarian (Tüttelmann et al., 2013) ethnic backgrounds; accordingly, elevated odds 
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ratios (1.8 to 3.0) were documented when comparing to parous controls (negative 
history for infertility or miscarriage) in German (Tüttelmann et al., 2013, Bogdanova 
et al., 2007), UK (Demetriou et al., 2015), Italian (Tiscia et al., 2009), and Japanese 
(Miyamura et al., 2011) cohorts. In accordance with the proposed physiological role 
of M2/ANXA5 haplotype in embryonic anticoagulation, several studies have showed 
similar paternal (father) risk in RPL couples (Demetriou et al., 2015, Tüttelmann et 
al., 2013). 
 
1.4.3 Revised ANXA5 protective shield model 
Gathering all information above (from Chapter 1.4), it was affirmed that M2/ANXA5 
carrying placental would have reduced ANXA5 mRNA expression with lowered 
ANXA5 protein on syncytiotrophoblast resulting a predisposing factor for various 
thrombophilia related obstetric complications.  
Previously, Rand et al. (1997) proposed that the aPLs disrupt the ability of 
ANXA5 to form two-dimensional structure, resulting in a lower affinity for this 
protein, which consequently favours the binding of coagulation-factor complexes. 
However, the authors did not explain why aPLs disrupt the ability of ANXA5. 
Recently, Bogdanova and her co-researchers reported an increased M2/ANXA5 carrier 
rate in obstetric APS patients, hence this prompted them to propose a ‘genetic’ model 
for disrupted ANXA5 shielding (Bogdanova et al., 2012). This revised model could 
explain the emerge of aPLs in the first instance (Figure 1.8 B ‘genetic’ versus Figure 
1.8 A ‘immunologic model’).  
In brief, their hypothesis narrated a predisposing factor, M2/ANXA5 haplotype, 
leads to attenuated coverage of exposed anionic phospholipid surfaces with clusters of 
ANXA5. Because of the inefficient shielding: (a) coagulation factors can compete for 
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phospholipid binding; and (b) there would be an enhanced exposure of phospholipid 
antigenic determinants that would lead to aPLs development then would further disrupt 
the ANXA5 protective shield. 
 
 
 
Figure 1.8 The ANXA5 protective shield model. (A) ‘immunologic’ versus (B) 
‘genetic’ revised model.  
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1.5 RPL in Malaysia 
Malaysia is a multi-ethnic society with different cultural and socioeconomic 
backgrounds. Malay is the largest ethnic group (55%) in Malaysia. The incident of 
pregnancy loss in Malaysia was 23% according to Survey on Health and Family 
planning (Arshat et al., 1985).  
Since the two most common causes of inherited thrombophilia (FVL and PTm) 
are virtually absent in Asians, especially in Southeast Asian individuals (Rees et al., 
1996); and only two publications (Yusoff et al., 2002, Ayadurai et al., 2009) reported 
the prevalence of FVL and PTm (1% and 0.3%, respectively) in RPL Malay. There are 
no official data regarding RPL incidence among Malay to date. Based on the statistics 
available from the Malaysian Population and Family Survey (MPSF), 14% of early 
pregnancy losses are recorded from total pregnancies (Tey et al., 2012). However, this 
reported abortion rate could be an underestimate. Notably, a high proportion of 
pregnancy losses at the Sultan Abdul Halim Hospital from 2013 to 2015, 2296/2575 
(89.2%), occurred in Malay women. The spontaneous abortion rate in Malay women 
at this hospital was 20.3% from a total of 11,306 admissions, although no records were 
available on RPL. 
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1.6 Objectives 
Owing to the high pregnancy loss rate and the scarcely studied of genetic aspect of 
RPL in Malaysia, the aims of the present study were  
1) To determine the frequency of M2/ANXA5 haplotype in a cohort of Malays;  
2)  To elucidate whether M2/ANXA5 haplotype is an independent RPL risk 
factor in the Malay population;  
3)  To estimate the power of M2/ANXA5 haplotype in Malay population, after 
confirming the potential of M2/ANXA5 haplotype as risk factor;  
4) To examine the circulating ANXA5 levels in  
i) non-pregnant and pregnant women with or without history of RPL,  
ii) M2/ANXA5 carriers vs. non M2/ANXA5 carriers of these clinically 
defined groups;  
5) To develop a method for the detection of Annexin A5 variants for screening 
tests of RPL, providing a more precise assessment of individual disease 
risks; 
6) To determine the role of M2/ANXA5 haplotype and RPL in published 
literatures via meta-analysis.  
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Figure 1.9 An overview of the study design of M2/ANXA5 haplotype and RPL. Detail of each 
study design will be presented in each chapter.  
  
21 
 
CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Chemical and reagents 
All common chemicals (analytical grade) and reagents were used without further 
purification and purchased from Sigma-Aldrich (Missouri, United States) and Merck 
(New Jersey, United States) unless specified below or in the text. 
 
2.2 Ethical Approval 
The present study was approved by the Human Ethics Research Committee of the 
Universiti Sains Malaysia (USMKK/PPP/JEPeM [245.3.(2)]) and the National 
Institutes of Health, Ministry of Health, Malaysia (NMRR-11-1044-9519), Appendix 
A. The study was carried out in accordance with The Code of Ethics of the World 
Health Organization (Declaration of Helsinki). The controls and subjects who agreed 
to participate in this study have signed an informed consent before collection of 
peripheral blood samples. 
 
2.3 DNA Extraction and genotyping 
Blood samples were collected in a 3 ml of BD Vacutainer™ plastic blood collection 
tubes (New Jersey, United States) contained K2 Ethylenediaminetetraacetic acid 
(EDTA). The sample collected was then centrifuged at 1,600 × g for 15 minutes (min) 
at room temperature. Buffy coat was aliquoted and stored at -80 °C until further used 
for DNA extraction. 
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Genomic DNA extraction was carried out using commercially available kit 
(Omega Bio-tek Inc., Norcross, USA) according to the manufacturer’s protocol. The 
extracted DNA was carried out by PCR prior to DNA sequencing. The PCR reaction 
was carried out as described in Bogdanova et al. (2007) with minor modification as 
following. Optimized PCR reactions were performed on 100 ng of genomic DNA in a 
total reaction volume of 25 µL. The PCR mixture contained: 1 × PCR reaction buffer 
(Biotools, Spain); 1 mM MgCl2 (Biotools, Spain); 5% dimethyl sulfoxide (DMSO); 
0.2 µM of each (forward: ANXA5.P + ex1.Fwd and reverse: ANXA5.P + ex1.Rv) 
primer; 200 µM dNTPs; 100 - 200 ng genomic DNA and 1 U Taq polymerase 
(Biotools, Spain). The primers used are listed in Table 2.1. Cycling conditions were as 
follows: initial denaturation at 95 °C for 5 min; followed by 25 cycles of amplification; 
95 °C for 30 s; 63 °C for 30 s; 72 °C for 30 s. The final extension was performed at 
72 °C for 5 min. 
 
 
Table 2.1 Primers for genotyping of M2/ANXA5 haplotype. 
Primer Name Primer Sequence 
Size Tm 
Amplicon 
Size 
ANX5.P +ex1.Fwd 
ANX5.P+ex1.Rv 
5’- CCGAGCCCTGGACAGCTCCCCA-3’ 
5’- GCCCCGCGACCACGCTCTCCTCT- 3’ 
22 bps 
23 bps 
67.9 °C 
69.5 °C  
439 bps 
 
 
The PCR products were purified using MultiScreenTM PCR plates (Millipore, 
Massachusetts, United States). Purified amplicons were directly sequenced in 96-well 
plates using the BigDye Terminator Cycle Sequencing Ready Reaction Kit 
(ABI/Perkin-Elmer, Massachusetts, United States); sequencing reactions were 
analyzed on an ABI PRISMw 3700 DNA Analyzer (ABI/Perkin-Elmer, 
23 
 
Massachusetts, United States). DNA sequences were analyzed on FinchTV version 1.4 
(Geospiza Finch Suite, Perkin Elmer, Massachusetts, United States). Genotypes were 
scored in table format and four digits coded for further processing (Table 2.2). 
 
 
Table 2.2 Codes for M2/ANXA5 genotyping. 
Genotyping Codes 
N/N 0101 
N/M2 0103 
M2/M2 0303 
 
 
2.4 Allele-Specific PCR 
The developed allele-specific PCR is based on the principle of nested PCR. The first 
PCR reaction was carried out as described in Chapter 2.3. Second PCR comprises of 
two independently parallel allele-specific reactions (wild-type and M2/ANXA5 
haplotype, respectively). The primers sequence used are listed in Table 2.3. The final 
optimized protocol included 1 µL of 10 × diluted first PCR product as template, 1 × 
PCR reaction buffer (Biotools, Spain), 0.5 mM MgCl2 (Biotools, Spain), 0.2 µM of 
each primer, 5% dimethyl sulphoxide (DMSO) and 1.25 U Taq polymerase. The PCR 
cycling condition was the same as first PCR reaction. Then, the second PCR product 
was analyzed on 2% agarose gel in 1 × TAE at 100 V for 25 min. The amplicon size 
is 139 bps. 
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Table 2.3 List of Allele-Specific Primers. 
Primer Name Primer Sequence Size Tm Amplicon 
size 
AS Normal-Fwd 
AS Normal-Rv 
5’-TGGCGCGGCCGGCCTGCGGTTGG- 3’ 
5’-GAGATGCAGACGCTGAAGGATCC- 3’ 
23 bps 
23 bps 
75.6 °C 
59.6 °C 
139 bps 
AS M2-Fwd 
AS M2-Rv 
5’-TGGCGCGGCCGGCCTGCGGTTGA- 3’ 
5’- GAGATGCAGACGCTGAAGGATCT-3’ 
23 bps 
23 bps 
74.7 °C 
58.7 °C 
139 bps 
  
